June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Clinical Utility of Multifocal Pupillographic Objective Perimetry in Type 1 Diabetes
Author Affiliations & Notes
  • Ted Maddess
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Lauren Baker
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Andrew James
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Caitlin Coombes
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Veronica Cheung
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Melody Melody Chiou
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Maria Kolic
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Christopher Nolan
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Faran Sabeti
    ARC Vision Centre, Eccles Inst Neurosci, Australian National University, Canberra, ACT, Australia
  • Footnotes
    Commercial Relationships Ted Maddess, Seeing Machines (F), Seeing Machines (P), EyeCo (I); Lauren Baker, None; Andrew James, Seeing Machines, Inc (P); Caitlin Coombes, None; Veronica Cheung, None; Melody Melody Chiou, None; Maria Kolic, SeeingMachines Ltd (E); Christopher Nolan, None; Faran Sabeti, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 218. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ted Maddess, Lauren Baker, Andrew James, Caitlin Coombes, Veronica Cheung, Melody Melody Chiou, Maria Kolic, Christopher Nolan, Faran Sabeti; Clinical Utility of Multifocal Pupillographic Objective Perimetry in Type 1 Diabetes. Invest. Ophthalmol. Vis. Sci. 2013;54(15):218.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the sensitivity and specificity of five variants of multifocal pupillographic objective perimetry (mfPOP) for discriminating controls from patients with type 1 diabetes (T1D) presenting with nil to non-proliferative diabetic retinopathy (NPDR).

 
Methods
 

25 T1D patients (37.9 ± 2.44 years, 12 females, mean duration 22.5 ± 10.1 years) and 23 normal (36.0 ± 2.58 years, 12 females) subjects were recruited. Pupillary contraction amplitudes and times-to-peak responses to red/green, yellow and blue dichoptic stimuli with 44 test regions/eye extending, to either ±15° or ±30°. Disease severity was based on either ETDRS scores from fundus photos; or scores based or factors from correlations between 18 patient variables, which were mainly based on blood analyses, but included peripheral neuropathy, and advanced glycation end-products.

 
Results
 

Factor scores based mainly on renal function, HBA1c and BMI were the best indicator of diabetic damage as measured by mfPOP. In eyes with no or mild NPDR, red/green mfPOP stimuli extending to ±30° achieved the highest ROC area under the curve (AUC) of 0.95 ± 0.05 (mean ± SE) for delay deviations and 0.91 ± 0.05 when amplitude deviations were considered. In moderate NPDR eyes diagnostic accuracy improved to 1.00 ± 0.05 for blue and yellow protocols.

 
Conclusions
 

The results suggest that red/green stimuli presented within the central 30° of fixation achieved good diagnostic power to determine diabetes status in eyes with minimal to no retinopathy. MfPOP may be a useful clinical tool in evaluating and monitoring eyes with early NPDR.

 
Keywords: 499 diabetic retinopathy • 642 perimetry • 667 pupil  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×